GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Net Debt Paydown Yield %

TCRT (Alaunos Therapeutics) Net Debt Paydown Yield % : 0% (As of Dec. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Alaunos Therapeutics's Net Debt Paydown Yield % was 0%.


Alaunos Therapeutics Net Debt Paydown Yield % Historical Data

The historical data trend for Alaunos Therapeutics's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Net Debt Paydown Yield % Chart

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.22 -6.13 -5.23 118.03

Alaunos Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.88 118.03 69.62 124.04 -

Competitive Comparison of Alaunos Therapeutics's Net Debt Paydown Yield %

For the Biotechnology subindustry, Alaunos Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Net Debt Paydown Yield % falls into.



Alaunos Therapeutics Net Debt Paydown Yield % Calculation

Alaunos Therapeutics's Net Debt Paydown Yield % for the quarter that ended in Sep. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( - )/5.156025
=173.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Alaunos Therapeutics  (NAS:TCRT) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Alaunos Therapeutics Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2617 Bissonnet Street, Suite 225, Houston, TX, USA, 77005
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129

Alaunos Therapeutics Headlines